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TabletingAbstract This study aimed to examine the adhesion of glibenclamide 5 mg tablets to the tools of
compression machines. This problem is not commonly reported in the literature, since it is consid-
ered as tacit knowledge. The starting point was the implementation of three technical alternatives:
changing the parameters of compression, evaluating the humidity of the powder blend and the man-
ufacturer of the lubricant magnesium stearate. The adhesion was directly related to the character-
istics of magnesium stearate from different manufacturers, and the feasibility of evaluating powder
ﬂow characteristics by different techniques that are not routinely followed in various pharmaceuti-
cal companies. In vitro dissolution tests showed that the magnesium stearate manufacturer can
inﬂuence on the dissolution proﬁle of glibenclamide tablets. This study presented various aspects
of tablet adhesion to compression machine punches. Troubleshooting approaches can be, most
of times, conducted based on previous experience, or an experimental research needs to be imple-
mented in order to have conﬁdent results.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Solid dosage forms, in particular tablets, dominate the global
pharmaceutical landscape. Different dosage forms have chan-
ged over time, mainly by the use of excipients, which have dis-
tinct functions in formulations (Sastry et al., 2000). Many
difﬁculties in the manufacture of tablets, however, are still
quite common in factories around the world. Among these
difﬁculties is the adhesion of tablets to the tools of
compression machines. Adhesion may have different causes
Table 1 Components of Glibenclamide 5 mg formulation.
Formulation Function
Glibenclamide Active principle (hypoglycemic)
Mannitol powder Diluent
Sodium lauryl sulfate Surfactant
Microcrystalline cellulose 102 Diluent/agent compression
Colloidal silicon dioxide Flow enhancer/absorbent
Magnesium stearate Lubricant/nonstick/sliding
Sodium croscarmellose Disintegrant
446 J. Boniatti et al.and consequences of varying degrees, and can lead to failure in
entire production batches. There are few research studies on
this subject in the literature. This problem is typically resolved
by trial and error, although has been reported that the use of
more advanced techniques, such as determining the force ex-
erted by the punch and dies, can predict this phenomenon
(Fu¨hrer, 1996; Picker-Freyer, 2008). Evaluation of force ex-
erted is of great value, since a commonly accepted hypothesis
for adhesion is the interaction between the powder particles
and the metal surface of punches.
Several factors may be related to the origin of adhesion,
including: manufacturing process (adjustment of the compres-
sive force and of the contact area between tools and formula-
tion powder), formulation (use of lubricants and other
excipients), conditions of blends (humidity) and equipment
(integrity and cleanliness of the punches) (Fu¨hrer, 1996; Pick-
er-Freyer, 2008). In a manufacturing process, adhesion can be
seen as a serious or critical deviation, depending on the
amount of mass lost (Alderborn, 2005). In an attempt to ex-
plain this deviation, three possibilities were evaluated: (a)
change in the compression process, (b) drying the blend to re-
duce its humidity and (c) the inﬂuence of lubricant on the com-
pression process.
Magnesium stearate is the most widely used lubricant in the
pharmaceutical industry in manufacturing of tablets and cap-
sules, due to its capacity to reduce friction. However, it should
be noted that the lubricant amount can signiﬁcantly affect the
product performance and quality, causing problems such as:
decrease in content uniformity, decrease in tablet hardness, in-
crease in tablet disintegration time, decrease in dissolution rate
and decrease in bioavailability. Thus, it is recommended to use
the minimum quantity of lubricant required (Andre`s et al.,
2001; Wada and Matsubara, 1994). A large number of studies
have reported that variations in physical and chemical proper-
ties of magnesium stearate have great inﬂuence on its lubricat-
ing action. Currently, it is known that variables such as
molecular structure, crystallinity, water content, thermal sta-
bility and granular properties are able to inﬂuence the func-
tional properties of the material in question (Bracconi et al.,
2005; Wang et al., 2010). Particle size and speciﬁc surface area
of magnesium stearate may be key factors inﬂuencing its lubri-
cation efﬁciency (Wang et al., 2010).
It is important to note that materials supplied by different
manufacturers are unlikely to be of exactly the same physical
properties, but lot to lot variability of materials obtained from
the same manufacturer is less likely to present a problem
(Wang et al., 2010). Another parameter that can inﬂuence
compression is the moisture of the powder blend and also
the relative humidity of the manufacturing environment. It is
necessary to identify the moisture range in which the particu-
late material shows good performance to carry out the com-
pression process. If the relative humidity can increase the
rate and extent of water absorption by the formulation, it is
very likely that adhesion will be evident in the ﬁnal product.
Furthermore, the humidity has a direct inﬂuence on the lubri-
cant added to the formulation (Alderborn, 2005).
With regard to magnesium stearate, it is known that its
functionality is based on the fact that water and air penetrate
into spaces between crystalline particles, increasing the move-
ment of these particles. This mechanism reduces the forces nec-
essary to break the crystalline structure of magnesium stearate,
which facilitates their spread on the surface to be lubricated.However, the crystalline form found in commercial batches
of magnesium stearate depends on the process for preparing
the excipient and on the humidity to which the material was
exposed after the manufacturing process (Rajala and Laine,
1995; Wang et al., 2010).
The adhesion of tablets to the tools of compression ma-
chines was observed by Farmanguinhos, a pharmaceutical lab-
oratory linked to the Brazilian Ministry of Health, during the
manufacture of glibenclamide 5 mg tablets. Therefore, the
technical group developed a research in attempt to solve the
case and to continue to manufacture the product without
problems.
2. Materials and methods
2.1. Materials
Glibenclamide (Cadila Pharmaceuticals LTDA), mannitol
powder (Launcher International), sodium lauryl sulfate (Cog-
nis Brasil LTDA), microcrystalline cellullose 102 (Blanver
Farmoquı´mica LTDA), silicon dioxide colloidal (Cabot Cor-
poration) e sodium croscarmellose (Blanver Farmoquı´mica
LTDA). Magnesium stearate was supplied by different manu-
facturers whose names are not mentioned here.
2.2. Methods
2.2.1. Preparation of formulations
Table 1 shows all the components used for manufacturing gli-
benclamide 5 mg tablets. Glibenclamide and magnesium stea-
rate concentrations were 4.17% and 1%, respectively. The
concentrations of other components were in accordance with
the recommendations of ofﬁcial compendium of the area.
The manufacturing process was carried out by direct com-
pression, i.e., the active ingredient and the excipients were
mixed and then, directly compressed into tablets. The powder
blend was added to a ‘‘V’’ blender (Lawes) and compression
occurred in a 35 punch rotary tablet machine (Manesty
BB4). All tests were performed under the same environmental
conditions in the manufacturing rooms, with temperature
about 20 C and relative humidity about 33%. Thus, these
parameters were disregarded.
2.2.2. Tests of changing the compression parameters
All tests were conducted with a low rate of compression and
with an increased pressure, i.e., higher compression force
resulting in tablets with higher tensile strength. The same blend
of the industrial batch with the problem of adhesion was used.
The tablet hardness range was ﬁxed from 14.0 to 19.0 Kp.
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The same blend of the previous test was used, but it was oven
dried until reaching the moisture content of 2.2%, considering
the initial moisture of 3.6%. The dried blend was compressed
and it was observed the appearance of adhesion to it.
2.2.4. Tests with different lubricant manufacturers and
assessment of blend storage time
The blend that generated the problem of adhesion during the
industrial manufacture was used; therefore it contained the
same batch of magnesium stearate. To evaluate the inﬂuence
of magnesium stearate batches, three formulations sets (1, 2
and 3) were produced, each one composed of 5 formulations
(FMS1, FMS2, FMS3, FMS4 and FMS5). The variation
among them was only the time between the powder blending
and compression. In group 1, formulations were blended and
compressed on the same day; in group 2 compression occurred
7 days after; group 3 had a period of 14 days between blending
and compression.
2.2.5. Preparation of powder blend
The quantitative formulation (drug and excipient composition)
used was the same for all tests. Each batch had a total mass of
2 kg. All raw materials were sieved through a 16 mesh sieve.
The powders were added in a V blender at a rotation speed
of 66 rpm for 15 min. Then, magnesium stearate was added
and blending continued for 5 min more. At the end of this step,
samples from different batches were taken and evaluated by
the following tests: loss on drying, particle size (sieving), ﬂow
measurement, angle of repose and bulk (loose) and tapped
(compressed) densities.
2.2.6. Evaluation of powder blend properties
Powder blend properties were evaluated by different tests, such
as particle size and size distribution, ﬂow index, angle of re-
pose, Hausner ratio and Carr’s index and loss on drying.
2.2.6.1. Powder particle size and size distribution. Particle size
determination (powder particle size and size distribution) was
performed as described in the Brazilian Pharmacopoeia 5th
ed. (2010). This test is a mechanical analysis, which uses a sha-
ker to vibrate the sieves. Standardized sieves (80, 100, 115, 150,
200 and 250 mesh) were stacked on top of one another. An
amount of 25 g was added to the larger mesh sieve and submit-
ted to vibration for 60 min. Calculations were performed to
determine the powder formulation homogeneity and represen-
tativeness of each particle size.
2.2.6.2. Apparent and tapped densities. For bulk and tapped
volumes determination, 10.0 g of powder was added in a
100.0 mL graduated cylinder properly calibrated. The volume
occupied was measured and to it was given the name of appar-
ent (bulk) volume. Bulk density was calculated as the ratio of
the mass to its apparent volume. After observing the initial
volume, the cylinder was mechanically tapped, using Erweka
SVM22 apparatus, and volume readings were taken. Vertical
movements occurred at a ﬁxed drop of 3 mm (±10%) and
at a nominal rate of 250 taps per minute (Picker-Freyer,
2008). After 500 and 750 taps, the corresponding tappedvolume was read. Only when the difference between V500 and
V750 was smaller than 2%, 500 additional taps were performed.
Tapped density was determined as the ratio of the mass to its
ﬁnal tapped volume.
2.2.6.3. Flow properties. Evaluation of blend ﬂow properties
was based on four parameters: angle of repose, Hausner ratio,
Carr’s (compressibility) index and ﬂow through an oriﬁce, all
listed and recommended by USP 32nd ed. (2009). A granulate
tester Erweka GTB, which provides an automated measure-
ment of the angle of repose, was used. In order to determine
the Hausner ratio (HR) and the compressibility index (IC), it
was needed to know the apparent (Vi) and tapped (Vf) vol-
umes, deﬁned according to methodology described in previous
item. Hausner ratio and compressibility index were calculated
using Eqs. 1 and 2, respectively.
HR ¼ Vi
Vf
ð1Þ
IC ¼ Vf Vi 100
Vf
ð2Þ
The ﬂow rate of each formulation was also studied using a ﬂow
tester equipment Erweka GTB. The powder blends were
poured through funnels with opening diameters of 15 and
25 mm; the ﬁrst one agitation (speed 3) was used. The funnel
was opened and the time needed for 100 g to ﬂow was mea-
sured (USP, 2009).
2.2.6.4. Determination of loss on drying. The moister content
was determined by measuring the loss on drying using an infra-
red radiation analyzer Gehaka IV2000. Samples were homoge-
neously distributed on aluminum plates and heated by infrared
radiation to constant weight (Brazilian Pharmacopeia, 2010).
The endpoint determination was performed in the automatic
mode.
2.2.7. Manufacturing and quality control of the tablets
2.2.7.1. Manufacturing of glibenclamide tablets. Glibenclamide
5 mg tablets were produced by direct compression using a ro-
tary tablet machine (Manesty/BB4) with a 7.0 mm round ﬂat
punch.
2.2.7.2. Quality control of glibenclamide tablets. 2.2.7.2.1.
Visual characteristics’ control. Some visual characteristics eval-
uated during the production process were shape, color and
presence of any foreign material. In addition to visual assess-
ment, optical microscopy was used for better visualization of
tablets’ surface characteristics. A magniﬁcation of 6.25· was
used in an optical stereo microscope Olympus SCX9.
2.2.7.2.2. Average weight. For each formulation, samples
were taken at the beginning, middle and end of the compres-
sion run. Twenty tablets were weighed individually (for each
step). The average weight of 120.0 mg was established, with
a variation of 7.5% (Brazilian Pharmacopeia, 2010).
2.2.7.2.3. Thickness, diameter and hardness. The thickness,
diameter and hardness of tablets were simultaneously deter-
mined using a speciﬁc equipment Erweka ZT71. For each for-
mulation, 10 tablets were sampled at the beginning, middle and
end of the compression run (Brazilian Pharmacopeia, 2010), in
a total of 30 tablets for each step. In this study, tablets’
Figure 1 Microphotographs of Glibenclamide 5 mg tablets. (A)
Intact tablet, with no signs of adhesion and (B) Glibenclamide
5 mg tablet with signiﬁcant grip on the top.
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2.2.7.2.4. Friability test. Twenty tablets were weighed and
placed in the friability tester Erweka that revolved at 25 rpm
for 4 min. After this time, the tablets were weighed and the per-
centage loss was determined. No cracked, cleaved or broken
tablets can be present at the end of the test. A maximum
weight loss from the samples of not more than 1.5% was con-
sidered acceptable (Brazilian Pharmacopeia, 2010).
2.2.7.2.5. Disintegration test. Disintegration test was con-
ducted as described in the Brazilian Pharmacopoeia 5th ed.
(2010), using an automatic disintegrator Erweka ZT71. The
time limit established was 15 min and the averages of disinte-
gration time were used.
2.2.7.2.6. In vitro dissolution studies. Dissolution tests were
conducted, according to the previously described procedure
(Qureshi and McGilveray, 1999), at 37 ± 0.5 C in 900 mL
of phosphate buffer solution pH 7.40 ± 0.05 at 75 rpm. A
USP dissolution apparatus II (paddle method) (Distek 6100)
was used for studies. Aliquots of 10 mL were withdrawn at
10, 20, 30, 60, 90 and 120 min and immediately assayed using
a UV Shimadzu UV-1800 spectrophotometer at a wavelength
of 227 nm. Cumulative percentages of the dissolved drug from
the tablets were calculated and plotted versus time. Dissolution
studies for each formulation were performed in six replicates.
The dissolution proﬁles were compared through a model inde-
pendent method, using the difference factor (f1) and the simi-
larity factor (f2), Eqs. 3 and 4, respectively.
f1 ¼ 100
Xn
t¼1
jRt  Tjt
Xn
t¼1
Rt
0
BBB@
1
CCCA ð3Þ
f2 ¼ 50 log 1þ 1
n
 Xn
t¼1
ðRt  TtÞ2
 !" #0:5
 100
8<
:
9=
; ð4ÞTable 2 Physical test results of glibenclamide 5 mg tablets (n= 30) for formulations varying from the manufacturer of magnesium
stearate.
Test Formulation
FMS1 FMS2 FMS3 FMS4 FMS5
Average weight (mg)
1 120.00 ± 2.60 120.36 ± 2.67 121.16 ± 3.63 119.60 ± 2.99 120.93 ± 3.39
2 122.03 ± 4.03 120.36 ± 1.66 120.53 ± 1.67 122.16 ± 1.26 120.40 ± 1.68
3 121.21 ± 1.45 120.21 ± 1.07 120.31 ± 1.42 120.43 ± 1.12 120.30 ± 1.27
Hardness (kgf)
1 8.45 ± 0.24 7.78 ± 0.63 8.26 ± 0.46 8.25 ± 1.27 8.04 ± 1.09
2 8.42 ± 0.55 7.73 ± 1.03 7.73 ± 1.03 8.45 ± 0.55 7.24 ± 0.57
3 7.84 ± 0.35 8.95 ± 0.32 7.81 ± 0.27 7.92 ± 0.41 7.95 ± 0.34
Friability (%)
1 0.07 ± 0.05 0.05 ± 0.05 0.04 ± 0.00 0.09 ± 0.04 0
2 0 0 0 0 0.12 ± 0.04
3 0.03 ± 0.02 0.02 ± 0.04 0.03 ± 0.02 0.01 ± 0.02 0.03 ± 0.02
Disintegration (seg)
1 63.11 ± 18.61 27.50 ± 7.93 43.33 ± 15.77 43.33 ± 16.69 35.44 ± 20.56
2 35.44 ± 15.48 19.66 ± 9.98 45.66 ± 25.09 33.55 ± 15.33 15.50 ± 10.11
3 35.22 ± 13.07 20.88 ± 17.91 23.22 ± 17.71 25.66 ± 14.78 26.77 ± 16.27
Particle size (lm)
1, 2 e 3 15.83 64.22 87.62 85.30 82.73
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The phenomenon of adhesion is quite common in the manu-
facture of tablets. Blending, granulation, compression and
coating steps increase the interaction forces between the active
ingredients and excipients and this can be problematic during
the compression process because it can increase the adhesion
between tablets and tools of compression machines. In time
consuming manufacturing processes, in which the contact be-
tween the metal surfaces of the dies and punches with the pow-
der is exacerbated, adhesion can become more evident. There
were addressed three possibilities for solving the problem of
glibenclamide 5 mg tablet adhesion: increase hardness, dry
the blend and use magnesium stearate supplied by different
manufacturers.
Moisture adsorption by solid forms determines the need to
control humidity during production and storage of medicines.
Virtually moisture interacts with a pharmaceutical solid during
all production steps (Miller and York, 1985). The two funda-
mental forces that can affect ﬂow properties of powders are
friction and cohesion (Miller and York, 1985). Cohesion is
the mutual attraction and resistance to separation of contact-
ing powder of similar material. With regard to pharmaceutical
formulations, interactions occur not only between individual
particles of active ingredients, but also between them and the
excipients present in formulations.
Moisture can inﬂuence the strength of interaction between
solid particles in at least three ways: (a) can be adsorbed in
the surface and inﬂuence the surface energy, (b) can change
the surface conductivity and thus the particle electrostatic
charge and (c) can precipitate in regions adjacent to capillaries
where there is a real contact (Hiestand, 1996).Table 3 Results of the assessment of the ﬂow of mixtures prepared
Test Formulation
FMS1 FMS2
Angle of repose ()
1 45.13 ± 0.65 44.63 ± 0.16
2 44.66 ± 0.04 45.80 ± 0.96
3 44.96 ± 0.05 44.80 ± 0.37
Apparent density (g/mL)
1 0.45 0.50
2 0.43 0.41
3 0.41 0.47
Bulk density (g/mL)
1 0.55 0.58
2 0.52 0.50
3 0.50 0.55
Hausner ratio
1 1.22 1.17
2 1.21 1.20
3 1.20 1.16
Carr’s index
1 18.18 15.00
2 17.39 16.66
3 16.67 14.27Both alternatives, increased hardness and drying the ﬁnal
blend, were able to solve the adhesion problem. Because drying
the blend was effective, it was evident that the humidity had an
impact on the observed adhesion and this moisture must be
coming from the manufacturing process. However, it should
be considered that the method used was direct compression
and that the environment humidity was adequate. Thus, this
variable is dependent only on the amount of moisture in the
formulation components. The increase in hardness due to low-
er machine speed and increase in compression strength also
showed an improvement in the appearance of adhesion of
the tablets. This alternative, however, aggravates the process
productivity.
The increase in tablet hardness was primarily evaluated by
reducing the manufacturing speed and increasing the compres-
sion force applied to the tablets. The test results were effective,
eliminating the problem of adhesion. The values obtained with
the new speciﬁcations were hardness of 17.09 kp, thickness of
2.50 mm, diameter of 6.88 mm, friability of 0% and disintegra-
tion in 67 s. Despite the good results obtained, it should be
mentioned that the use of high hardness value ﬁxed for com-
pression, is not a good alternative for the pharmaceutical
industry, because production can be impaired due to the
slower process.
The drying of the powder blend before compression was
carried out in a drying oven until reaching moisture of 2.2%.
After the drying process, it was not observed the adhesion of
tablet and furthermore lower hardness values were obtained.
The results showed hardness of 7.89 kp, thickness of
2.60 mm, diameter of 6.89 mm, friability of 0.12% and disinte-
gration in 21 s. It is noteworthy that for both tests the results
were expressed according to ofﬁcial recommendations..
FMS3 FMS4 FMS5
45.06 ± 1.06 44.33 ± 0.61 44.60 ± 0.32
45.16 ± 0.59 44.83 ± 1.00 44.20 ± 0.99
45.76 ± 0.09 45.30 ± 0.65 46.06 ± 0.30
0.41 0.47 0.41
0.50 0.45 0.43
0.41 0.50 0.45
0.50 0.55 0.50
0.50 0.52 0.50
0.50 0.50 0.52
1.20 1.16 1.20
1.05 1.10 1.21
1.20 1.20 1.21
16.66 14.28 16.66
5.00 9.09 17.39
16.66 16.66 16.66
Table 4 Results of ﬂow through oriﬁce of mixture loss on drying (in seconds/100 g).
Group Formulationsa
FMS1 FMS2 FMS3 FMS4 FMS5
15 mm 25 mm 15 mm 25 mm 15 mm 25 mm 15 mm 25 mm 15 mm 25 mm
1 12.7 3.0 13.3 3.0 13.9 4.3 13.4 3.3 12.9 3.7
2 12.6 2.9 13.3 2.7 13.4 4.1 13.4 3.5 13.5 3.6
3 12.8 2.8 12.8 2.8 12.0 3.6 12.4 3.4 13.1 3.4
a Tests performed with opening of 15 mm were with agitation speed in 3 and were performed with 25 mm without shaking.
Table 5 Results of ﬂow through an oriﬁce (in seconds/100 g).
Group Formulations
FMS1 FMS2 FMS3 FMS4 FMS5
1 5.7 4.7 5.2 4.4 6.1
2 4.4 3.6 3.7 4.3 4.4
3 4.7 3.6 3.7 3.7 3.7
Figure 2 Dissolution proﬁles of glibenclamide tablets with different magnesium stearate batches.
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magnesium stearate supplied by different manufacturers. In
the speciﬁc case of the formulation under study, magnesium
stearate is the lubricant and its properties can have a direct im-
pact on the ﬁnal properties of the tablets produced. Excipients
have been widely discussed in the literature, especially those
with lubricant action. No report, however, was published (in
the research carried out) showing in detail the characteristics
necessary for a better lubricant action. It is known that magne-
sium stearate has different degrees of hydration (Ertel and
Carstensen, 1988; Swaminathan and Kildsig, 2001), crystal
structure (Ertel and Carstensen, 1988), fatty acid composition
(Sharpe et al., 1997), and surface area (Swaminathan et al.,
2006), among other important features to its lubricating
action.
It is of great importance for the pharmaceutical industry to
establish very rigorous speciﬁcations to avoid gaps in quality
of medicines manufactured. It is known that small variations
in the characteristics of the active ingredients and excipientscan have direct effect in the manufacturing process (Wada
and Matsubara, 1994), stability (Airaksinen, 2005) and bio-
availability (Andre`s et al., 2001; Wada and Matsubara, 1994)
of medicines.
Pharmaceutical raw materials speciﬁcation must conform
to materials performance in a real situation of production.
Thus, the basic formulation described in Table 1 was used
varying only the quality of magnesium stearate with the aim
of evaluating different samples and determine the most ade-
quate one to be used in the industrial manufacturing of this
product. Five different lubricant manufacturers were evaluated
and the excipients showed to be physical and chemically differ-
ent (results not presented here).
The main objective was to evaluate the compression perfor-
mance of each formulation and, consequently, each lubricant.
Other work is under development to establish the structure–
performance correlation.
The main objective of these tests was to evaluate the
adhesion to the tablet tools, and also check the different
Galenic approaches in troubleshooting of glibenclamide tablet adhesion in compression 451physical properties presented by tablets produced with differ-
ent manufacturers of magnesium stearate. The results of the
physical tests performed are shown in Table 2. Tablets were
also analyzed by microscopy for better visualization of adhe-
sion points in tablets. The microphotographs are shown in
Fig. 1. The adhesion area is indicated with a red arrow.
It is a common practice in the pharmaceutical industry to
prepare blends for batches of a campaign to manufacture a
particular product. These blends were not compressed immedi-
ately, but only a few days after. During this time, some
changes may occur, including an increase in the amount of
water adsorbed on the surface of the powder blend. This
adsorption can lead to adhesion of the tablet to tools. To eval-
uate the impact of storage time on the adhesion results, blends
prepared with different manufacturers of magnesium stearate
were stored for 7 and 14 days, after this period they were com-
pressed. These periods were selected in order to simulate the
expected time for compression in routine production.
According to above observations, all values found in pro-
cess control tests (average mass, disintegration, friability and
hardness) were within the established parameters. The formu-
lation that showed a signiﬁcant adhesion was FMS2 – group 2,
however it should be noted that the FMS1 – group 1 also
showed signs of this problem, although less intense. The values
of average mass did not present wide variations, even with for-
mulation FMS2, as shown in Fig. 1. Granulometric analysis
showed difference in terms of particle sizes of the blends
FMS1 and FMS2.
An evaluation of major importance for industrial applica-
tion is the powder ﬂow. This property has a direct impact on
various parameters of the process and in the actual ﬁnal prod-
uct (Rios, 2006). Flowability is not exclusively an inherent
property of the material but results from a combination of
physical properties and equipment used in processing (Prescott
and Barnum, 2000). Among the tests used to evaluate ﬂowabil-Table 6 Results of the pairwise comparison of formulation of glibe
criteria.
Formulation f-criteria FMS1 F
FMS1 f1
– 1
f2
4
FMS2 f1
13.96 –
f2
42.05
FMS3 f1
5.99 2
f2
51.32 3
FMS4 f1
5.66 8
f2
61.20 5
FMS5 f1
9.29 1
f2
48.44 3ity of pharmaceutical powders are Carr index (or compressibil-
ity), Hausner ratio, ﬂow through an oriﬁce and the angle of
repose. Of all of them, the ﬂow through an oriﬁce is a more
realistic prediction of the material behavior, since it is the only
direct analysis of the ﬂowability. The other tests are indirect
parameters, which take into account calculations based on
other measures.
Magnesium stearate, in addition to its lubricating function,
has also a sliding action, which facilitates the ﬂow from hop-
pers into the die cavity. Thus, this magnesium stearate action
should be reﬂected in powder ﬂow depending on the sliding
capacity of this excipient. In the present study, this evaluation
was also performed (Table 3).
Table 3 shows the angle of repose obtained for different
formulation. The angle of repose can be deﬁned as the con-
stant three-dimensional angle measured relatively to the hori-
zontal base, assumed by a cone-like pile of material formed
when the powder is passed through a funnel. An angle of re-
pose lower than 40 indicates good ﬂowability, conversely an
angle superior to 40 is an indication of cohesiveness (Sar-
raguc¸a et al., 2010), although USP describes other ranges of
classiﬁcation. This test did not allow distinguishing between
ﬂow properties of the formulations. The results were very close
and there was no correlation between them and adhesion.
Hausner ratio and Carr index were more suitable to differenti-
ate between formulations because the values obtained were
able to successfully distinguish the ﬂow properties. Further-
more, Hausner ratio and Carr index showed a closer correla-
tion with tablet adhesion.
Flow through an oriﬁce results are reported in Table 4.
First, it is important to mention that this speciﬁc ﬂow test de-
mands a methodology development work. There are different
hole diameters, which allow a more realistic evaluation
depending on the ﬂow properties of the evaluated powders.
The smaller the hole diameter, the more difﬁcult will be to ﬂownclamide tablets, employing the difference (f1) and similarity (f2)
MS2 FMS3 FMS4 FMS5
3.96 5.99 5.66 9.29
2.05 51.32 61.20 48.44
20.51 8.75 16.26
34.69 53.99 35.44
0.51 – 9.76 7.86
4.69 45.61 51.21
.75 9.76 – 7.25
3.99 45.61 44.66
6.26 7.86 7.25 –
5.44 51.21 44.66
452 J. Boniatti et al.the powder. During the methodology development, the smaller
diameter holes are used, because they can be more discrimina-
tory between different samples. The ﬂow, however, must be
uniform, showing no signiﬁcant variation in the analysis.
In this work, hole diameter of 15 mm was selected to begin
the test, but the powder did not ﬂow and portions were re-
tained in the funnel. Thus, a possibility was to use the equip-
ment with a shaker, which facilitates the ﬂow by revolutions
at a constant rate. The results with agitation were very repro-
ducible. In order to evaluate a conﬁguration that would ana-
lyze the ﬂow without the need for agitation, which would be
a more ‘‘real’’ assessment of the powder intrinsic ﬂowability,
it was used a 25 mm opening. The results were quite reproduc-
ible and discriminatory. Thus, this conﬁguration should be
adopted for future analysis of this material. Moreover, the test
also allowed discrimination between the samples that did and
did not presented good results during compression. Those that
adhered to the punches (FMS1 and FMS2) presented a lower
ﬂow rate than those that did not adhered. Therefore, this test,
for its simplicity, proved to be an interesting evaluation for the
magnesium stearate performance, complementing its
functionality.
Table 5 shows the values of loss on drying of the blends. A
considerable change in moisture with time was observed, but
the results were not uniform. Some values decreased, while
others increased. Within group 2, FMS2 presented the highest
adhesion, and there was no correlation between the values of
loss on drying with the adhesion of the blends.
In vitro dissolution test is a valuable tool to identify the
inﬂuence of key formulation and manufacturing factors, like
excipients, binder and mixing effects. Therefore, dissolution
testing plays an important role, providing better control of
production process and assuring consistent quality of products
(Maggio et al., 2008). The results of in vitro dissolution studies
showed the inﬂuence of magnesium stearate characteristics in
dissolution proﬁle (Fig. 2).
The corresponding f1 and f2 values were calculated using
data acquired at all points. All possible comparisons were car-
ried out and the results are given in Table 6.
When comparing FMS1 against FMS3 and FMS4, one can
see that the difference (5.99 and 5.66, respectively) and the sim-
ilarity factors (51.32 and 61.20, respectively) indicated that
their dissolution proﬁles were similar. FMS2 and FMS4 exhib-
ited acceptable difference and similarity factors (8.75 and
53.99, respectively). Finally, comparing FMS3 to FMS5, both
difference and similarity factors (7.86 and 51.21, respectively)
were acceptable, indicating that their dissolution proﬁles
should be considered similar (Table 6). The other comparisons
showed unacceptable difference and/or similarity values, indi-
cating that these formulations were not similar. Therefore, in
some cases the use of magnesium stearate from different man-
ufacturers affected the dissolution of glibenclamide tablets.
4. Conclusion
This study presented various aspects of tablet adhesion to
compression machine punches. The case was glibenclamide
5 mg tablets in an industrial situation. Three possibilities were
proposed, and the implementation and reﬁnement of the spec-
iﬁcations of the lubricant magnesium stearate was the one
more feasible. The other two (increased hardness and dryingthe blend) are prone to reduce productivity, and lead to
changes in the process already registered in the Brazilian
Health Surveillance Agency (ANVISA) of Brazil. The results
showed that the adhesion was directly related to the character-
istics of magnesium stearate from different manufacturers, and
the feasibility of evaluating powder ﬂow characteristics by dif-
ferent techniques that are not routinely followed in various
pharmaceutical companies. The results also contributed to
the development of excipient functionality studies. In vitro dis-
solution tests showed that the magnesium stearate manufac-
turer can inﬂuence on the dissolution proﬁle of glibenclamide
tablets. Troubleshooting approaches can be, most of times,
conducted based on previous experience, or an experimental
research needs to be implemented in order to have conﬁdent
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